Analyst firms · Mizuho · RLMD
Mizuho RLMD price target and rating history
Relmada Therapeutics Inc. (RLMD) · Health Care
Mizuho rates Relmada Therapeutics Inc. (RLMD) Outperform with a $10 price target, as of its latest action on Nov 19, 2025. It has published 3 rating actions on RLMD since November 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a RLMD price target in the last 12 months, the median target is $12.
- Current rating
- Outperform
- Price target
- $10
- Median target, all firms
- $12
- Actions on RLMD
- 3
Mizuho price target on RLMD
Every Mizuho rating on RLMD
- Nov 19, 2025
- Dec 5, 2024
- Nov 18, 2021
How other firms rate RLMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $12 | Jun 18, 2026 |
| Piper Sandler | Overweight | $12 | Mar 24, 2026 |
| Leerink Partners | Outperform | $8 | Jan 23, 2026 |
| Jefferies | Buy | $69 | Dec 22, 2025 |
Questions about Mizuho and RLMD
- What is Mizuho's price target for RLMD?
- Mizuho's latest stated price target for Relmada Therapeutics Inc. (RLMD) is $10, from its action on Nov 19, 2025.
- What is Mizuho's rating on RLMD?
- Mizuho rates RLMD Outperform, a bullish rating, as of Nov 19, 2025.
- When did Mizuho last change its view on RLMD?
- On Nov 19, 2025, Mizuho upgrades to Outperform from Neutral, price target $10.
- How does Mizuho's RLMD target compare with other analysts?
- Across 4 firms with a RLMD price target in the last 12 months, the median target is $12.
All Mizuho ratingsRLMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.